Summary

Overview
The Global Acute Cerebral Ischemic Stroke Drug Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
The human brain is a very metabolically active organ, accounting for around 25% of a person's metabolic needs despite only making up 2.5% of the average person's body weight. As a result, changes in blood flow can cause the brain to become extremely sensitive. Through an action known as cerebrovascular autoregulation, complex homeostatic systems keep cerebral blood flow at a roughly constant rate of 50 ml/100 g of brain tissue each minute. One of the most frequent mechanisms of brain dysfunction and damage is cerebral ischemia, which occurs when blood flow is impeded.
The incidence of acute cerebral ischemic stroke is on the rise, which is a major market driver. The aging of the population, rising rates of risk factors including diabetes and hypertension, and changes in lifestyle all have a role in the growing incidence of stroke.
Advancements in stroke therapy choices are the result of ongoing research and development initiatives. Antiplatelet medications, thrombolytic medicines, and anticoagulants are becoming more widely available and efficient, which benefits patient outcomes.
Market Dynamics: Drivers
The Increasing Stroke Incidence
A stroke is a type of cerebrovascular event that may be fatal or severely disabling. With over 13 million instances and 5.5 million fatalities per year, it is the second biggest cause of mortality globally. Stroke survivors experience long-term functional disabilities as a result of permanent brain damage. About 85% of all strokes are acute ischemic strokes, which are brought on by blockages in the blood supply to the brain.
After the initial 3 to 4.5 hours, there are no recognized medical treatments for this type of stroke. New medicines are urgently needed to both improve clinical outcomes with increased efficacy and safety and to expand the window of opportunity for patients to undergo thrombolytic therapy after the onset of a stroke.
Additionally, according to the Global Burden of Illness project, there were 1,175,778 incident stroke cases in India. According to studies, there are between 116 and 163 stroke cases per 100,000 people in India. In India, stroke is the fifth most common cause of disability and the fourth most common cause of death. More than 80% of the estimated 15 million new strokes anticipated to occur globally by 2050 would occur in low- and middle-income nations.
Side Effects of Acute Cerebral Ischemic Stroke Drug
Stroke treatment can be costly, especially with newer and more sophisticated drugs. High treatment expenses can be a major obstacle, especially in areas with poor insurance coverage or limited access to healthcare services. Anticoagulants, which are used to treat strokes, can have negative effects and need to be closely monitored. Some patients may be discouraged from obtaining or continuing therapy due to safety concerns and the possibility of consequences. Because clinical trials for stroke treatments sometimes require large sample numbers and specialized patient populations, they can be difficult to conduct. Regulatory obstacles and the length of time needed for drug development can impede market expansion.
Segment Analysis
The global acute cerebral ischemic stroke drug market is segmented based on drug type, end-user, and region.
The thrombolytics segment accounted for approximately 51.2% of the market share
Intravenous thrombolytics have been used to treat acute ischemic stroke. Although research into the effectiveness of tenecteplase is ongoing, tissue plasminogen activator (TPA) is the only thrombolytic drug currently licensed by the Food and Drug Administration for the treatment of acute ischemic stroke. Although studies suggest that TPA may be safe and beneficial if delivered as long as 4.5 hours after the onset of symptoms, it is only recommended for the treatment of acute ischemic stroke if it can be given within 3 hours of the onset of symptoms.
For instance, in May 2021, Biogen Inc. and TMS Co., Ltd., Biogen acquired TMS-007, an experimental treatment for acute ischemic stroke, from TMS. Positive results from a Phase 2a study served as the foundation for Biogen's decision to purchase TMS-007. The trial achieved its main safety goal with no symptomatic intracranial hemorrhage (sICH) occurrence and showed favorable effects on both brain blood vessel reopening and patient functional recovery.
Patients received doses up to 12 hours after the onset of stroke symptoms; the median time to therapy for patients receiving TMS-007 was 9.5 hours, compared to 9.3 hours for those receiving a placebo. Every patient who received TMS-007 had doses that went over the allowed window for using thrombolytic medications.
Geographical Analysis
Advanced Healthcare Infrastructure
North America has been a dominant force in the global acute cerebral ischemic stroke drug market. Access to stroke care has increased due to the adoption of telemedicine and remote monitoring technology, especially in isolated or underserved locations. Telemedicine makes it possible to monitor patients remotely and schedule timely consultations, which speeds up the response time for stroke cases.
Stroke consistently ranks as the fifth most common cause of death in the United States and is one of the most common vascular disorders in the globe. According to the 2019 AHA report on heart disease and stroke statistics, 20 million Americans older than 20 are estimated to have experienced a stroke. Each year, 795,000 people experience a stroke. Nearly 75% of cases involve adults over the age of 65, and prevalence rises with age.
Compared to Caucasians, strokes are more common among African Americans and Hispanics. With a little female predominance due to a decline in male frequency over the previous 15 years, the prevalence of stroke is roughly the same in both genders.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global acute cerebral ischemic stroke drug market. Due to concerns about getting sick or the pressure on the healthcare system during the COVID-19 pandemic, many people put off or avoided seeking treatment for diseases that weren't related to the virus. This delay in getting help could have hampered the prompt treatment of an acute cerebral ischemic stroke. Increased knowledge of stroke symptoms and the significance of obtaining urgent medical attention is essential because delayed treatment can result in worse results.
By Drug Type
• Thrombolytics
• Antiplatelet Agents
• Anticoagulants
• Neuroprotective Agents
• Others
By End-user
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Sun Pharmaceutical Industries, Pharmazz Inc, Biogen, Boehringer Ingelheim International GmbH and others.
Key Developments
• In September 2023, Pharmazz, Inc., a Willowbrook, Illinois-based biopharmaceutical company, entered into a license agreement with India's Sun Pharmaceutical Industries Ltd. to introduce Tyvalzi (Sovateltide) in India. Sovateltide is recommended for acute cerebral ischemic stroke.
Why Purchase the Report?
• To visualize the global acute cerebral ischemic stroke drug market segmentation based on drug type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of acute cerebral ischemic stroke drug market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global acute cerebral ischemic stroke drug market report would provide approximately 38 tables, 44 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by End-user
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Side Effects of Acute Cerebral Ischemic Stroke Drug
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The Increasing Stroke Incidence
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Thrombolytics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antiplatelet Agents
7.4. Anticoagulants:
7.5. Neuroprotective Agents
7.6. Others
8. By End-user
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
8.1.2. Market Attractiveness Index, By End-user
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Specialty Clinics
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Sun Pharmaceutical Industries*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Pharmazz Inc
11.3. Biogen
11.4. Boehringer Ingelheim International GmbH
11.5. Others
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us